Literature DB >> 9049219

Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation.

H Segal1, S Cottam, D Potter, B J Hunt.   

Abstract

Cirrhosis is associated with compromised hemostasis and coagulopathy during orthotopic liver transplantation (OLT). It has been suggested that hemostasis is better preserved during OLT in primary biliary cirrhosis (PBC) than other cirrhotic states. The aim of this study was to compare coagulation and fibrinolysis in 15 patients with PBC with 31 patients with other liver disease before and during OLT. Preoperatively, both groups had subnormal mean levels of prekallikrein, factor XIIa, antithrombin III (ATIII), plasminogen, and alpha2-antiplasmin. C1 esterase inhibitor and kallikrein inhibition in PBC was higher than the normal range (P < .01), but not in non-PBC. Non-PBC had lower median fibrinogen levels and shorter euglobulin clot lysis times (ECLT) (P < .05). Tissue plasminogen activator (tPA) antigen levels did not differ between groups but were elevated from the normal range, as were median thrombin-antithrombin complexes (TAT). Plasminogen activator inhibitor (PAI) activity was significantly higher in PBC (0.0041). Perioperatively in the PBC group during the early anhepatic phase of OLT, there was more thrombin generation, as evidenced by higher TAT levels (P = .0455) and less hyperfibrinolysis with longer ECLTs. We hypothesize that there is a preserved capacity to generate thrombin and less fibrinolytic activation during the anhepatic phase of OLT, and we suggest that, in PBC, the use of antifibrinolytic agents may have an adverse effect.

Entities:  

Mesh:

Year:  1997        PMID: 9049219     DOI: 10.1002/hep.510250332

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  19 in total

1.  The coagulation system contributes to alphaVbeta6 integrin expression and liver fibrosis induced by cholestasis.

Authors:  Bradley P Sullivan; Paul H Weinreb; Shelia M Violette; James P Luyendyk
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

Review 2.  New insights into the coagulopathy of liver disease and liver transplantation.

Authors:  M Senzolo; P Burra; E Cholongitas; A-K Burroughs
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

3.  The antifibrinolytic drug tranexamic acid reduces liver injury and fibrosis in a mouse model of chronic bile duct injury.

Authors:  Nikita Joshi; Anna K Kopec; Keara Towery; Kurt J Williams; James P Luyendyk
Journal:  J Pharmacol Exp Ther       Date:  2014-03-14       Impact factor: 4.030

4.  Fibrin deposition following bile duct injury limits fibrosis through an αMβ2-dependent mechanism.

Authors:  Nikita Joshi; Anna K Kopec; Jessica L Ray; Holly Cline-Fedewa; Atta Nawabi; Timothy Schmitt; Rance Nault; Timothy R Zacharewski; Cheryl E Rockwell; Matthew J Flick; James P Luyendyk
Journal:  Blood       Date:  2016-02-26       Impact factor: 22.113

Review 5.  Massive haemorrhage in liver transplantation: Consequences, prediction and management.

Authors:  Stuart Cleland; Carlos Corredor; Jia Jia Ye; Coimbatore Srinivas; Stuart A McCluskey
Journal:  World J Transplant       Date:  2016-06-24

Review 6.  Perioperative thrombotic complications in liver transplantation.

Authors:  Paolo Feltracco; Stefania Barbieri; Umberto Cillo; Giacomo Zanus; Marco Senzolo; Carlo Ori
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

7.  Fibrinogen deficiency increases liver injury and early growth response-1 (Egr-1) expression in a model of chronic xenobiotic-induced cholestasis.

Authors:  James P Luyendyk; Karen M Kassel; Katryn Allen; Grace L Guo; Guodong Li; Glenn H Cantor; Bryan L Copple
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

Review 8.  An approach to the diagnosis and treatment of bleeding disorders in infants.

Authors:  Thomas C Abshire
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 9.  Coagulopathy in liver disease: Lack of an assessment tool.

Authors:  Annabel Blasi
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

10.  Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy?

Authors:  Marco Senzolo; Maria Teresa Sartori; Ton Lisman
Journal:  HPB (Oxford)       Date:  2009-09       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.